Get the Stockscreener App
8.87
7.78%
0.64
Omeros Corporation stock is traded at $8.87, with a volume of 1.22M.
It is up +7.78% in the last 24 hours and up +12.71% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$8.23
Open:
$8.05
24h Volume:
1.22M
Relative Volume:
0.37
Market Cap:
$628.89M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-4.7181
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
+12.71%
1M Performance:
+12.71%
6M Performance:
+185.21%
1Y Performance:
+14.75%
1-Day Range:
$8.04
$8.91
1-Week Range:
$7.72
$9.55
52-Week Range:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
8.87 | 583.51M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid (NASDAQ:OMER) - Seeking Alpha
What technical signals suggest for Omeros Corporation stockMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com
Omeros Corporation Stock Analysis and ForecastInsider Selling Patterns & Free Stock Trading Workshops - earlytimes.in
Is Omeros Corporation stock cheap compared to fundamentalsIPO Watch & Technical Entry and Exit Tips - newser.com
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Omeros (NASDAQ:OMER) Shares Down 5.6%Should You Sell? - MarketBeat
Here's Why Shares in Theravance Biopharma Exploded Today - AOL.com
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com
How strong is Omeros Corporation stock revenue growthBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Omeros (NASDAQ:OMER) Stock Price Up 8.1%Time to Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Q3 2025 Earnings Call Transcript - Insider Monkey
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying - AOL.com
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch - AOL.com
Omeros Corporation’s Earnings Call Highlights Strategic Moves - TipRanks
test-commerce-234 - AOL.com
Omeros (OMER) Q3 2025 Earnings Call Transcript - The Globe and Mail
Published on: 2025-11-17 02:29:02 - newser.com
Omeros Corporation stock outlook for YEARJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER) - MarketBeat
What candlestick patterns are forming on Omeros CorporationWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Omeros (NASDAQ:OMER) Shares Gap UpHere's Why - MarketBeat
Is Omeros Corporation meeting your algorithmic filter criteriaMarket Activity Report & Real-Time Chart Breakout Alerts - newser.com
Ranking Omeros Corporation among high performing stocks via toolsJuly 2025 Highlights & Community Supported Trade Ideas - newser.com
Omeros (NASDAQ:OMER) Cut to Sell at Wall Street Zen - MarketBeat
Omeros files automatic mixed securities shelf - MSN
Omeros (NASDAQ:OMER) Announces Quarterly Earnings Results - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Omeros (OMER) Receives Analyst 'Buy' Rating with Stable Price Ta - GuruFocus
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Benzinga
D. Boral Capital Maintains Omeros (OMER) Buy Recommendation - MSN
Omeros: Q3 Earnings Snapshot - CTPost
Omeros Corp (OMER) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges By GuruFocus - Investing.com Canada
Can Omeros Corporation stock resist market sell offsOptions Play & Free Community Supported Trade Ideas - newser.com
Omeros Corp (OMER) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges - Yahoo Finance
Omeros Corporation Reports Q3 2025 Financial Results - TipRanks
Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close - Nasdaq
Omeros Sets Sights On Big Pharma Deal And FDA Green Light - Finimize
Omeros Inks Big Deal With Novo Nordisk And Eyes FDA Nod - Finimize
Omeros Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Omeros Q3 2025 sees narrower loss, stock drops - Investing.com Nigeria
Omeros (OMER) Set for Transformative Growth with Key Developments - GuruFocus
Omeros Corp. R (3O8.F) Q3 FY2025 earnings call transcript - Yahoo Finance
BRIEF-Omeros Corporation Q3 EPS USD -0.47 - TradingView
Omeros Corporation Reports Third Quarter 2025 Financial Results - The Joplin Globe
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):